Overview Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumour-infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognise and attack diverse cancer cells in each patient. The company’s first product, AMTAGVI (lifileucel), an autologous T-cell therapy using TIL, was recently approved by the Therapeutic Goods Administration (TGA) and is indicated for the treatment of advanced melanoma. Iovance is preparing to launch this novel treatment in the Australian market. The Commercial Lead, Australia is the senior commercial leader accountable for establishing, commercialising and scaling Iovance’s business in the Australian market. This role owns the Australian commercial strategy and profit-and-loss performance, including revenue, operating expenses, forecasting, resource allocation and achievement of business objectives for AMTAGVI and Proleukin. The Commercial Lead will direct the full sales cycle—from market development, account planning, referral generation and patient identification through treatment‑centre activation, completed patient infusions, revenue generation and ongoing account growth. This individual will report directly to the SVP, Global Access, Operations and Proleukin. The Commercial Lead will lead the authorisation and commercial activation of AMTAGVI treatment centres and provide operational and quality oversight after authorisation. The individual will build executive and clinical relationships across treatment centres and referral networks; ensure medical, nursing, laboratory, pharmacy,



quality and administrative stakeholders are prepared to deliver TIL therapy; and align internal functions to move eligible patients from identification and referral through tumour procurement, manufacturing coordination, treatment scheduling, completed infusion and revenue recognition. As the senior business leader for Australia, the individual will set the country commercialisation strategy, lead launch and market development, and be accountable for commercial performance in the near term and in preparation for national public access. The role will represent the Australian business in global planning, investment, forecasting and performance discussions and will build the commercial capabilities and organisation required as the market grows.

Location:
Melbourne or Sydney preferred. This role requires regular travel across Australia, including Queensland, New South Wales, Victoria, Western Australia, and other states and territories as business needs dictate. Essential Functions and Responsibilities
- Own and lead the Australian commercialisation strategy, launch plan and ongoing business performance for AMTAGVI and Proleukin.
- Hold profit-and-loss accountability for the Australian business, including revenue, operating expenses, forecasts, budgets, investments, resource allocation and profitability.
- Establish annual and long-range commercial plans, performance measures and resource priorities aligned with global business objectives.
- Lead the full sales cycle across authorised treatment centres and referral networks,



from chance identification, account planning and customer education through patient identification, referral, treatment scheduling, completed infusion, revenue generation and ongoing account growth.
- Achieve patient infusion, demand and revenue targets for AMTAGVI and Proleukin while maintaining compliance with applicable laws, regulations and company policies.
- Build and manage the Australian commercial forecast using treatment‑centre readiness, referral activity, patient identification, scheduling, manufacturing, infusion and revenue data.
- Develop and maintain executive, clinical and operational relationships with treatment centres, referral sites, health-service leaders, clinicians, Commonwealth and state health authorities, public and private funders, reimbursement stakeholders, hospital decision-makers and other partners required to establish and expand TIL therapy in Australia.
- Lead the TIL treatment‑centre authorisation process using risk-based tools for authorisation, training, monitoring and disqualification, and provide ongoing operational and quality oversight of authorised treatment centres.
- Lead operational meetings with medical leadership from medical oncology, surgery and cell therapy to establish a standard-of-care pathway for TIL therapy.
- Lead cross-functional treatment‑centre meetings with nursing, laboratory, pharmacy, quality and operational champions to develop product and patient workflows and remove barriers to treatment.
- Develop and execute training for authorised users and ensure access to chain-of-identity and chain-of-custody systems is provided to trained individuals.
- Lead cross-functional execution across Market Access, Treatment Centre Operations, Me

📌 Commercial Lead, Australia (Sydney)
🏢 Iovance Biotherapeutics
📍 Sydney